Hermann Einsele
Impact in
- Hematology top 0.01%
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Oncology top 0.02%
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
Papers in
- Hematology 525
- Multiple Myeloma Research and Treatments 347
- Hematopoietic Stem Cell Transplantation 111
- Oncology 370
- CAR-T cell therapy research 142
- Co-authors
- Jürgen Löffler (114 shared papers)Holger Frithjof Hebart (69 shared papers)Michael Hudecek (38 shared papers)Ulrike Schumacher (17 shared papers)Per Ljungman (22 shared papers)Stefan Tobias Knop (71 shared papers)Michael Boeckh (5 shared papers)Ralf Christian Bargou (50 shared papers)
- Journals
- Blood (197 papers)Leukemia (51 papers)Bone Marrow Transplantation (49 papers)Haematologica (35 papers)British Journal of Haematology (32 papers)
- Partner nations
- GermanyUnited StatesItaly
In The Last Decade
Hermann Einsele
1.0k papers receiving 58.0k citations
Hermann Einsele's Hit Papers
Peers
Comparison fields: 5 of 173
- Hematology 25.6k
- Oncology 23.0k
- Genetics 5.5k
- Immunology 8.6k
- Infectious Diseases 7.1k
Countries citing papers authored by Hermann Einsele
This map shows the geographic impact of Hermann Einsele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hermann Einsele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hermann Einsele more than expected).
Fields of papers citing papers by Hermann Einsele
This network shows the impact of papers produced by Hermann Einsele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hermann Einsele. The network helps show where Hermann Einsele may publish in the future.
Co-authors
The 25 scholars most cited alongside Hermann Einsele, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.0k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma Hit paper breakdown → | 2021 | 1948 |
| 2 | Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective Hit paper breakdown → | 2009 | 1396 |
| 3 | Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma Hit paper breakdown → | 2015 | 1112 |
| 4 | Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody Hit paper breakdown → | 2008 | 898 |
| 5 | Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival Hit paper breakdown → | 2011 | 780 |
| 6 | A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma Hit paper breakdown → | 2007 | 761 |
| 7 | Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group Hit paper breakdown → | 2016 | 741 |
| 8 | Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Hit paper breakdown → | 2014 | 696 |
| 9 | Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management Hit paper breakdown → | 2010 | 660 |
| 10 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study Hit paper breakdown → | 2011 | 652 |
| 11 | International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders Hit paper breakdown → | 2008 | 649 |
| 12 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report Hit paper breakdown → | 2015 | 641 |
| 13 | Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† Hit paper breakdown → | 2021 | 620 |
| 14 | Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2017 | 609 |
| 15 | Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial Hit paper breakdown → | 2009 | 597 |
| 16 | 2006 | 579 | |
| 17 | Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Hit paper breakdown → | 2014 | 578 |
| 18 | Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma Hit paper breakdown → | 2023 | 544 |
| 19 | 1997 | 496 | |
| 20 | The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells Hit paper breakdown → | 2019 | 443 |
About Hermann Einsele
Hermann Einsele is a scholar working on Hematology, Oncology, Immunology, Infectious Diseases and Genetics, having authored 1.0k papers that have together received 59.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (347 papers), CAR-T cell therapy research (142 papers), Antifungal resistance and susceptibility (121 papers), Protein Degradation and Inhibitors (112 papers), Hematopoietic Stem Cell Transplantation (111 papers), Fungal Infections and Studies (91 papers), Cytomegalovirus and herpesvirus research (87 papers) and Immune Cell Function and Interaction (76 papers). The work is most often cited by research in Hematology (25.6k citations), Oncology (23.0k citations), Genetics (5.5k citations), Immunology (8.6k citations) and Infectious Diseases (7.1k citations). Hermann Einsele has collaborated with scholars based in Germany, United States and Italy. Frequent co-authors include Jürgen Löffler, Holger Frithjof Hebart, Michael Hudecek, Ulrike Schumacher, Per Ljungman, Stefan Tobias Knop, Michael Boeckh, Ralf Christian Bargou, Jan Storek and Catherine Cordonnier. Their work appears in journals such as Blood, Leukemia, Bone Marrow Transplantation, Haematologica and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.